Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326025 · ClinicalTrials.gov registry record · Phase 1
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT02326025 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 49 participants.
The verdict
NCT02326025, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how the body handles olaratumab when it is given with another drug called doxorubicin. The safety and tolerability of these drugs will be studied. Each participant will complete two 21-day cycles in a fixed order. Participants who complete Cycle 2 may continue to receive olaratumab + doxorubicin for an additional six 21-day cycles and then may receive olaratumab alone until discontinuation criteria are met. Screening is required within 21 days prior to first dose. Part B was added in October, 2015 to assess how the body handles a higher dose of olaratumab when given with doxorubicin. Participants may only enroll in one part.
Interventions
- DRUG Doxorubicin
- DRUG Olaratumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2015-01-22 |
| Est. Completion | 2018-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02326025
The ClinicalTrials.gov registry entry for NCT02326025 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT02326025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02326025 about?
NCT02326025 is a clinical study titled "A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma". The purpose of this study is to assess how the body handles olaratumab when it is given with another drug called doxorubicin. The safety and tolerability of these drugs will be studied. Each participant will complete two 21-day cycles in a fixed order. Participants who complete Cycle 2 may continue...
What is the current status of trial NCT02326025?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2015-01-22. Estimated completion is 2018-11-02.
What interventions are being tested in trial NCT02326025?
The interventions under investigation include: Doxorubicin (DRUG), Olaratumab (DRUG).
Who is sponsoring clinical trial NCT02326025?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.